Skip to main content
SpringerLink
Log in

Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders

  • Review Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Since antiepileptic drugs (AEDs) are prescribed to treat various non-epilepsy-related disorders in addition to the fact that patients with epilepsy may develop concurrent disorders that will need treatment, the propensity for AEDs to interact with non-AEDs is considerable and indeed can present a difficult clinical problem. The present review details the pharmacokinetic and pharmacodynamic interactions that have been reported to occur with the new AEDs (eslicarbazepine acetate, felbamate, gabapentin, lacosamide, lamotrigine, levetiracetam, oxcarbazepine, perampanel, pregabalin, retigabine (ezogabine), rufinamide, stiripentol, tiagabine, topiramate, vigabatrin and zonisamide) and drugs used to treat non-epilepsy disorders. Interaction study details are described, as necessary, so as to allow the reader to take a view as to the possible clinical significance of particular interactions. Pharmacokinetic interactions relate to hepatic enzyme induction or inhibition and involved a variety of drugs including psychoactive drugs, cardioactive drugs, oral contraceptives, antituberculous agents, analgesics and antineoplastic drugs. A total of 68 pharmacokinetic interactions have been described, with lamotrigine (n = 22), topiramate (n = 18) and oxcarbazepine (n = 7) being associated with most, whilst lacosamide, pregabalin, stiripentol and vigabatrin are associated with none. Overall, only three pharmacodynamic interactions have been described and occur with oxcarbazepine, perampanel and pregabalin.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Patsalos PN, Bourgeois BF. The epilepsy prescriber’s guide to antiepileptic drugs. New York: Cambridge University Press; 2010.

    Book  Google Scholar 

  2. Johannessen LC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs. 2008;22:27–47.

    Article  Google Scholar 

  3. Patsalos PN, Froscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia. 2002;43:365–85.

    Article  PubMed  CAS  Google Scholar 

  4. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs)—part 1. Pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmacokinet. doi:10.1007/s40262-013-0087-0.

  5. da Vaz SM, Costa R, Soares E, Maia J, Falcao A, Almeida L, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of digoxin in healthy subjects. Fundam Clin Pharmacol. 2009;23:509–14.

    Article  Google Scholar 

  6. Rocha JF, Vaz-da-Silva M, Almeida L, Falcao A, Nunes T, Santos AT, et al. Effect of eslicarbazepine acetate on the pharmacokinetics of metformin in healthy subjects. Int J Clin Pharmacol Ther. 2009;47:255–61.

    Article  PubMed  CAS  Google Scholar 

  7. Falcao A, Vaz-da-Silva M, Gama H, Nunes T, Almeida L, Soares-da-Silva P. Effect of eslicarbazepine acetate on the pharmacokinetics of a combined ethinylestradiol/levonorgestrel oral contraceptive in healthy women. Epilepsy Res. 2013 Apr 6. pii: S0920-1211(13)00080-6. doi:10.1016/j.eplepsyres.2013.02.020. [Epub ahead of print].

  8. Bialer M, Soares-da-Silva P. Pharmacokinetics and drug interactions of eslicarbazepine acetate. Epilepsia. 2012;53:935–46.

    Article  PubMed  CAS  Google Scholar 

  9. Vaz-da-Silva M, Almeida L, Falcao A, Soares E, Maia J, Nunes T, et al. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study. Clin Ther. 2010;32:179–92.

    Article  PubMed  CAS  Google Scholar 

  10. Saano V, Glue P, Banfield CR, Reidenberg P, Colucci RD, Meehan JW, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther. 1995;58:523–31.

    Article  PubMed  CAS  Google Scholar 

  11. Tisdel KA, Israel DS, Kolb KW. Warfarin-felbamate interaction: first report. Ann Pharmacother. 1994;28:805.

    PubMed  CAS  Google Scholar 

  12. Busch JA, Radulovic LL, Bockbrader HN, Underwood BA, Sedman AJ, Chang T. Effect of Maalox TC on single-dose pharmacokinetics of gabapentin capsules in healthy subjects [abstract]. Pharm Res. 1992;9(Suppl 2):S315.

    Google Scholar 

  13. Lal R, Sukbuntherng J, Luo W, Vicente V, Blumenthal R, Ho J, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69:498–507.

    Article  PubMed  CAS  Google Scholar 

  14. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A. Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006;2:981–1007.

    Article  PubMed  CAS  Google Scholar 

  15. Feng MR, Ouellet D, Li W, Berna K, Ferreira S, Knowlton P, et al. Pharmacokinetic interaction of gabapentin and naproxen in rats and humans [abstract]. Clin Pharmacol Ther. 2003;73:P50.

    Article  Google Scholar 

  16. Depot M, Powell JR, Messenheimer JA Jr, Cloutier G, Dalton MJ. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther. 1990;48:346–55.

    Article  PubMed  CAS  Google Scholar 

  17. Ebert U, Thong NQ, Oertel R, Kirch W. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol. 2000;56:299–304.

    Article  PubMed  CAS  Google Scholar 

  18. Haan GJ, Efelbroek P, Bartels C. Changes in lamotrigine pharmacokinetics induced by antitubercular drugs [abstract]. Epilepsia. 2010;51(Suppl 4):26.

    Google Scholar 

  19. Schieber FC, Boulton DW, Balch AH, Croop R, Mallikaarjun S, Benson J, et al. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. Hum Psychopharmacol. 2009;24:145–52.

    Article  PubMed  CAS  Google Scholar 

  20. Burger DM, Huisman A, Van EN, Neisingh H, Van UP, Rongen GA, et al. The effect of atazanavir and atazanavir/ritonavir on UDP-glucuronosyltransferase using lamotrigine as a phenotypic probe. Clin Pharmacol Ther. 2008;84:698–703.

    Article  PubMed  CAS  Google Scholar 

  21. Reimers A, Skogvoll E, Sund JK, Spigset O. Drug interactions between lamotrigine and psychoactive drugs: evidence from a therapeutic drug monitoring service. J Clin Psychopharmacol. 2005;25:342–8.

    Article  PubMed  CAS  Google Scholar 

  22. Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry. 2004;37:63–8.

    Article  PubMed  CAS  Google Scholar 

  23. Harden CL, Herzog AG, Nikolov BG, Koppel BS, Christos PJ, Fowler K, et al. Hormone replacement therapy in women with epilepsy: a randomized, double-blind, placebo-controlled study. Epilepsia. 2006;47:1447–51.

    Article  PubMed  CAS  Google Scholar 

  24. van der Lee MJ, Dawood L, ter Hofstede HJ, de Graaff-Teulen MJ, van Ewijk-Beneken Kolmer EW, Caliskan-Yassen N, et al. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. Clin Pharmacol Ther. 2006;80:159–68.

    Article  PubMed  Google Scholar 

  25. Sidhu J, Job S, Bullman J, Francis E, Abbott R, Ascher J, et al. Pharmacokinetics and tolerability of lamotrigine and olanzapine coadministered to healthy subjects. Br J Clin Pharmacol. 2006;61:420–6.

    Article  PubMed  CAS  Google Scholar 

  26. Sabers A, Buchholt JM, Uldall P, Hansen EL. Lamotrigine plasma levels reduced by oral contraceptives. Epilepsy Res. 2001;47:151–4.

    Article  PubMed  CAS  Google Scholar 

  27. Sabers A, Ohman I, Christensen J, Tomson T. Oral contraceptives reduce lamotrigine plasma levels. Neurology. 2003;61:570–1.

    Article  PubMed  CAS  Google Scholar 

  28. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia. 2005;46:1414–7.

    Article  PubMed  CAS  Google Scholar 

  29. Sidhu J, Job S, Singh S, Philipson R. The pharmacokinetic and pharmacodynamic consequences of the co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol. 2006;61:191–9.

    Article  PubMed  CAS  Google Scholar 

  30. Contin M, Albani F, Ambrosetto G, Avoni P, Bisulli F, Riva R, et al. Variation in lamotrigine plasma concentrations with hormonal contraceptive monthly cycles in patients with epilepsy. Epilepsia. 2006;47:1573–5.

    Article  PubMed  CAS  Google Scholar 

  31. Tomson T, Luef G, Sabers A, Pittschieler S, Ohman I. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives. Neurology. 2006;67:1297–9.

    Article  PubMed  CAS  Google Scholar 

  32. Gidal BE, Sheth R, Parnell J, Maloney K, Sale M. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy. Epilepsy Res. 2003;57:85–93.

    Article  PubMed  CAS  Google Scholar 

  33. Gidal BE, Anderson GD, Rutecki PR, Shaw R, Lanning A. Lack of an effect of valproate concentration on lamotrigine pharmacokinetics in developmentally disabled patients with epilepsy. Epilepsy Res. 2000;42:23–31.

    Article  PubMed  CAS  Google Scholar 

  34. Christensen J, Petrenaite V, Atterman J, Sidenius P, Ohman I, Tomson T, et al. Oral contraceptives induce lamotrigine metabolism: evidence from a double-blind, placebo-controlled trial. Epilepsia. 2007;48:484–9.

    Article  PubMed  CAS  Google Scholar 

  35. Ohman I, Luef G, Tomson T. Effects of pregnancy and contraception on lamotrigine disposition: new insights through analysis of lamotrigine metabolites. Seizure. 2008;17:199–202.

    Article  PubMed  Google Scholar 

  36. Bigham S, McGuigan C, MacDonald BK. Reduced absorption of lipophilic anti-epileptic medications when used concomitantly with the anti-obesity drug orlistat. Epilepsia. 2006;47:2207.

    Article  PubMed  Google Scholar 

  37. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure. 1998;7:163–5.

    PubMed  CAS  Google Scholar 

  38. Waade RB, Christensen H, Rudberg I, Refsum H, Hermann M. Influence of comedication on serum concentrations of aripiprazole and dehydroaripiprazole. Ther Drug Monit. 2009;31:233–8.

    Article  PubMed  CAS  Google Scholar 

  39. Bullman J, Nicholls A, Van LK, Fleck R, Vuong A, Miller J, et al. Effects of lamotrigine and phenytoin on the pharmacokinetics of atorvastatin in healthy volunteers. Epilepsia. 2011;52:1351–8.

    Article  PubMed  CAS  Google Scholar 

  40. Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol. 2000;50:193–5.

    Article  PubMed  CAS  Google Scholar 

  41. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol. 2002;17:233–8.

    Article  PubMed  CAS  Google Scholar 

  42. Spina E, D’Arrigo C, Migliardi G, Santoro V, Muscatello MR, Mico U, et al. Effect of adjunctive lamotrigine treatment on the plasma concentrations of clozapine, risperidone and olanzapine in patients with schizophrenia or bipolar disorder. Ther Drug Monit. 2006;28:599–602.

    Article  PubMed  CAS  Google Scholar 

  43. Andersson ML, Bjorkhem-Bergman L, Lindh JD. Possible drug-drug interaction between quetiapine and lamotrigine–evidence from a Swedish TDM database. Br J Clin Pharmacol. 2011;72:153–6.

    Article  PubMed  CAS  Google Scholar 

  44. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther. 2000;85:77–85.

    Article  PubMed  CAS  Google Scholar 

  45. Kramer G, Tettenborn B, Flesch G. Oxcarbazepine-verapamil drug interaction in healthy volunteers [abstract]. Epilepsia. 1991;32(Suppl 1):70–1.

    Google Scholar 

  46. Pisani F, Fazio A, Oteri G, Artesi C, Xiao B, Perucca E, et al. Effects of the antidepressant drug viloxazine on oxcarbazepine and its hydroxylated metabolites in patients with epilepsy. Acta Neurol Scand. 1994;90:130–2.

    Article  PubMed  CAS  Google Scholar 

  47. Rosche J, Froscher W, Abendroth D, Liebel J. Possible oxcarbazepine interaction with cyclosporine serum levels: a single case study. Clin Neuropharmacol. 2001;24:113–6.

    Article  PubMed  CAS  Google Scholar 

  48. Zaccara G, Gangemi PF, Bendoni L, Menge GP, Schwabe S, Monza GC. Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine. Ther Drug Monit. 1993;15:39–42.

    Article  PubMed  CAS  Google Scholar 

  49. van den Bent MJ, Grisold W, Frappaz D, Stupp R, Desir JP, Lesimple T, et al. European Organization for Research and Treatment of Cancer (EORTC) open label phase II study on glufosfamide administered as a 60-minute infusion every 3 weeks in recurrent glioblastoma multiforme. Ann Oncol. 2003;14:1732–4.

    Article  PubMed  Google Scholar 

  50. Pursche S, Schleyer E, von Bonin M, Ehninger G, Said SM, Prondzinsky R, et al. Influence of enzyme-inducing antiepileptic drugs on trough level of imatinib in glioblastoma patients. Curr Clin Pharmacol. 2008;3:198–203.

    Article  PubMed  CAS  Google Scholar 

  51. Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia. 1999;40:783–7.

    Article  PubMed  CAS  Google Scholar 

  52. Angelopoulos P, Markopoulou M, Kyamidis K, Bobotas K. Neuroleptic malignant syndrome without fever after addition of oxcarbazepine to long-term treatment with amisulpride. Gen Hosp Psychiatry. 2008;30:482–4.

    Article  PubMed  Google Scholar 

  53. Perampanel (Fycompa). Summary of product characteristics. Eisai Europe Ltd.; 2012.

  54. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia. 2004;45(Suppl 6):13–8.

    Article  PubMed  CAS  Google Scholar 

  55. Crean CS, Tompson DJ. The effects of ethanol on the pharmacokinetics, pharmacodynamics, safety, and tolerability of ezogabine (retigabine). Clin Ther. 2013;35:87–93.

    Article  PubMed  CAS  Google Scholar 

  56. Bodd E, Gadeholt G, Christensson PI, Morland J. Mechanisms behind the inhibitory effect of ethanol on the conjugation of morphine in rat hepatocytes. J Pharmacol Exp Ther. 1986;239:887–90.

    PubMed  CAS  Google Scholar 

  57. Perucca E, Cloyd J, Critchley D, Fuseau E. Rufinamide: clinical pharmacokinetics and concentration–response relationships in patients with epilepsy. Epilepsia. 2008;49:1123–41.

    Article  PubMed  CAS  Google Scholar 

  58. Mengel HB, Jansen JA, Sommerville KW, Jonkman J, Wesnes K, Cohen A, et al. Tiagabine: evaluation of the risk of interaction with theophylline, warfarin, digoxin, cimetidine, oral contraceptives, triazolam, or ethanol [abstract]. Epilepsia. 1995;36(Suppl 3):S160.

    Google Scholar 

  59. Burstein AH, Boudreau EA, Theodore WH. Increase in tiagabine serum concentration with coadministration of gemfibrozil. Ann Pharmacother. 2009;43:379–82.

    PubMed  CAS  Google Scholar 

  60. Bialer M, Doose DR, Murthy B, Curtin C, Wang SS, Twyman RE, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet. 2004;43:763–80.

    Article  PubMed  CAS  Google Scholar 

  61. Topamax (Topiramate). Summary of product characteristics. Janssen-Cilag Ltd.; 2012.

  62. Marriott D, Levy R, Doyle T, Ray J. Posaconazole-induced topiramate toxicity. Ann Intern Med. 2009;151:143.

    Article  PubMed  Google Scholar 

  63. Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21:645–53.

    Article  PubMed  CAS  Google Scholar 

  64. Doose DR, Kohl D, Desai-Krieger D, Natarajan J, van Kemmen DP. No clinically significant effect of topiramate on haloperidol plasma concentration [abstract]. Eur Neuropsychopharmacol. 1999;9(Suppl 4):S357.

    Article  Google Scholar 

  65. Abraham G, Owen J. Topiramate can cause lithium toxicity. J Clin Psychopharmacol. 2004;24:565–7.

    Article  PubMed  Google Scholar 

  66. Rosenfeld WE, Doose DR, Walker SA, Nayak RK. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia. 1997;38:317–23.

    Article  PubMed  CAS  Google Scholar 

  67. Doose DR, Wang SS, Padmanabhan M, Schwabe S, Jacobs D, Bialer M. Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. Epilepsia. 2003;44:540–9.

    Article  PubMed  CAS  Google Scholar 

  68. Okumura J. Decrease in plasma zonisamide concentrations after coadministration of risperidone in a patient with schizophrenia receiving zonisamide therapy [abstract]. Int Clin Psychopharmacol. 1999;14(1):55.

    Google Scholar 

  69. Patsalos PN. Antiepileptic drug interactions—a clinical guide. New York: Springer; 2013.

    Book  Google Scholar 

Download references

Acknowledgments

This work was supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.

Financial disclosure

The author has no conflicts of interest in relation to this work.

Author information

Authors and Affiliations

  1. Department of Clinical and Experimental Epilepsy, Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK

    Philip N. Patsalos

  2. Epilepsy Society, Chalfont Centre for Epilepsy, Chalfont St Peter, UK

    Philip N. Patsalos

Authors
  1. Philip N. Patsalos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philip N. Patsalos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Patsalos, P.N. Drug Interactions with the Newer Antiepileptic Drugs (AEDs)—Part 2: Pharmacokinetic and Pharmacodynamic Interactions Between AEDs and Drugs Used to Treat Non-Epilepsy Disorders. Clin Pharmacokinet 52, 1045–1061 (2013). https://doi.org/10.1007/s40262-013-0088-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40262-013-0088-z

Keywords

Search

Navigation